Yes lilly not hard to do the maths and why they went down this path. Double digit royalties is the key.
The deal with Acadia will see the US company develop, manufacture and commercialise the drug for Rett and Fragile X, while Neuren will be paid milestones and royalties. Acadia gave Neuren $US10m on signing the deal and it also agreed to pay $US105m in developmental milestones, plus a further $US350m for sales milestones.
“One thing that people didn’t pick up on with this deal is the double-digit royalties we receive, which step up and deliver potentially immense value back to Neuren,” Dr Treagus said.
Neuren’s lead work earns US deal via The Australian, page-3
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.14 |
Change
-0.130(0.85%) |
Mkt cap ! $1.935B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.47 | $14.93 | $7.335M | 485.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7079 | $15.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.17 | 3189 | 3 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |